Altimmune/$ALT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Altimmune

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Ticker

$ALT
Sector
Health
Primary listing
NASDAQ

Employees

59
Headquarters
Gaithersburg, United States
Website
altimmune.com

Altimmune Metrics

BasicAdvanced
$314M
-
-$1.17
-0.01
-

What the Analysts think about Altimmune

Analyst ratings (Buy, Hold, Sell) for Altimmune stock.

Bulls say / Bears say

As of March 31, 2025, Altimmune reported cash, cash equivalents, and short-term investments totaling $150 million and secured a $100 million credit facility from Hercules Capital, strengthening its financial position for ongoing and upcoming trials (Reuters).
The FDA approved IND applications for pemvidutide in Alcohol Use Disorder and Alcohol-Associated Liver Disease during Q1 2025. Phase 2 trials are scheduled to begin in Q2 and Q3 2025, expanding Altimmune's pipeline beyond MASH (Reuters).
Altimmune has completed enrollment for its 212-patient Phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis (MASH), with key topline data expected in Q2 2025, presenting a significant near-term catalyst (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.

Altimmune Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Altimmune Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Altimmune News

AllArticlesVideos
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Benzinga3 weeks ago
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Business Wire4 weeks ago
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs